Sort
53,477 grants matching “addiction”
Targeting exploitable vulnerabilities in T-cell Lymphoma
$2,233,312Samuel Ng · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Center for Addiction and Disease Risk Exacerbation
$2,232,943Peter M. Monti · Brown University · P20 · FY2023 · GM
A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder.
$2,232,752Ian Gurrell · Astrazeneca Pharmaceuticals, Lp · UG3 · FY2022 · DA
Rat Genome Database
$2,232,697Mary E Shimoyama · Medical College Of Wisconsin · R01 · FY2019 · HL
South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling
$2,232,110Kenneth D. Tew · Medical University Of South Carolina · P20 · FY2018 · GM
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail
$2,231,473Michael Scott Gordon · Friends Research Institute, Inc. · UG1 · FY2020 · DA
Targeting the Ghrelin System for Novel Opioid Use Disorder Therapeutics
$2,230,347Kathryn A. Cunningham · University Of Texas Med Br Galveston · UG3 · FY2019 · DA
Center for Systems Neurogenetics of Addiction
$2,229,570Elissa J Chesler · Jackson Laboratory · P50 · FY2019 · DA
Biology of Neuroendocrine Peptides
$2,229,290Wylie W. Vale · Salk Institute For Biological Studies · P01 · FY2007 · DK
Revealing the single cell determinants of brain relevant to persistent HIV infection and opioid use disorder
$2,227,239Tariq M Rana · University Of California, San Diego · U01 · FY2025 · DA
EPPIC-Net Pain Research - Application for Clinical Trial and Related Activities (OT2)
$2,226,370Maurizio Fava · Massachusetts General Hospital · OT2 · FY2023 · NS
JCOIN Phase II Coordination and Translation Center
$2,225,909Faye S Taxman · George Mason University · U2C · FY2024 · DA
Frontal Striatal Systems and Dopamine in Normal and Pathological Behavior
$2,225,006Bruno Averbeck · National Institute Of Mental Health · ZIA · FY2021 · MH
UNIVERSITY OF TEXAS SPORE IN LUNG CANCER
$2,224,767University Of Texas Sw Med Ctr/Dallas · P50 · FY2000 · CA
Integrative Omics Center for Accelerating Neurobiological Understanding of Opioid Addiction (ICAN)
$2,223,259Eric O Johnson · Research Triangle Institute · P50 · FY2023 · DA
Reversing opioid-induced hypoxemia with novel thiol-based drugs without compromising analgesia in goats
$2,218,043Matthew Robert Hodges · Medical College Of Wisconsin · RF1 · FY2022 · DA
4/24 Healthy Brain and Child Development National Consortium
$2,217,469Julie A Kable · Emory University · U01 · FY2024 · DA
Parents' Translational Research Center
$2,217,201Kimberly C Kirby · Treatment Research Institute · P50 · FY2012 · DA
FLORIDA NODE OF THE DRUG ABUSE CLINICAL TRIALS NETWORK
$2,216,874University Of Miami School Of Medicine · U10 · FY2001 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail
$2,216,013Michael Scott Gordon · Friends Research Institute, Inc. · UG1 · FY2021 · DA
Characterization of neuronal ensembles activated during drug-induced behavior
$2,215,650Bruce Hope · National Institute On Drug Abuse · ZIA · FY2016 · DA
Synaptic Transmission: Modulation, Plasticity And Effects Of Drugs Of Abuse
$2,215,574David M Lovinger · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2009 · AA
Using Implementation Interventions and Peer Recovery Support to Improve Opioid Treatment Outcomes in Community Supervision
$2,214,943Rosemarie A Martin · Brown University · U01 · FY2019 · DA
Neurobiology of Substance Abuse & Addiction - Preclinical Studies
$2,213,543Nora D. Volkow · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2012 · AA
Disrupted Adenovirus Serotype 5-based Anti-cocaine Vaccine
$2,210,393Ronald G Crystal · Weill Medical Coll Of Cornell Univ · U01 · FY2014 · DA